Previous 10 | Next 10 |
Shares of Rockwell Medical Inc. (NASDAQ:RMTI) traded at a new 52-week low today of $0.81. This new low was reached on below average trading volume as 383,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. Potential upside of 23.5% exists for Roc...
Shares of Rockwell Medical Inc. (NASDAQ:RMTI) traded today at $0.78, breaking its 52-week low. So far today approximately 383,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Potential upside of 29.4% exists for Rockwell Medical Inc., based o...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Rockwell Medical (RMTI) has submitted a pre-IND meeting request with the FDA in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate ((FPC)), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in ...
WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a p...
Rockwell Medical ([[RMTI]] +6.7%) has extended its distribution agreement with its long-term distribution partner, Nipro Medical Corporation (NMC), for a period of three years through May 2024.With the extension of the original agreement signed in 2008, NMC will continue to distribute dialysi...
WIXOM, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it extended its dist...
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead to transformative treatments for iron deficiency in multiple disease st...
Rockwell Medical (RMTI) perks up 6% premarket after entering into an exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic AVNU (ferric pyrophosphate citrate injection) in Turkey. Under the terms of the license agreement, Drogsan will...
WIXOM, Mich. and ANKARA, Turkey, June 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, and Drogsan Pharmaceut...
News, Short Squeeze, Breakout and More Instantly...
Rockwell Medical Inc. Company Name:
RMTI Stock Symbol:
NASDAQ Market:
Rockwell Medical Inc. Website:
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company's President and Chief Executive Officer, Dr. Mark Strobeck ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second ...
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the ...